
Opinion|Videos|December 5, 2025
Payer and Prior Authorization Barriers
Panelists discuss how payer controls and prior authorization policies delay and derail LDL-lowering therapy.
Advertisement
Episodes in this series

Panelists discuss how payer utilization management and prior authorization processes delay therapy initiation and contribute to high abandonment rates.
The paperwork burden discourages prescribers and frustrates patients, often interrupting continuity of care. Panelists highlight that these barriers disproportionately affect lower-income populations and smaller practices.
They recommend policy reforms that balance cost control with clinical flexibility, enabling timely treatment for high-risk individuals.
Advertisement
Related to this article

Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.

These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.

Admilparant 60 mg met the ALOFT-IPF primary end point, significantly improving FVC change vs placebo at 52 weeks in idiopathic pulmonary fibrosis.

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.

The conference session featured updates on several clinical trials, including the BRUNELLO trial, for treatment of diabetic macular edema (DME).

Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
3
MedHaul Closes Care Gaps With Single Stop for Getting Patients to Appointments
4
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
5

